Purpose: Circulating tumor DNA (ctDNA) has the potential to guide therapy selection and monitor treatment response in patients with metastatic cancer. However, germline and clonal hematopoiesis–associated alterations can confound identification of tumor-specific mutations in cell-free DNA (cfDNA), often requiring additional sequencing of tumor tissue. The current study assessed whether ctDNA-based treatment response monitoring could be performed in a tumor tissue–independent manner by combining ultra-deep targeted sequencing analyses of cfDNA with patient-matched white blood cell (WBC)-derived DNA. Experimental Design: In total, 183 cfDNA and 49 WBC samples, along with 28 tissue samples, from 52 patients with metastatic colorectal cancer participating in the prospective phase III CAIRO5 clinical trial were analyzed using an ultra-deep targeted sequencing liquid biopsy assay. Results: The combined cfDNA and WBC analysis prevented false-positives due to germline or hematopoietic variants in 40% of patients. Patient-matched tumor tissue sequencing did not provide additional information. Longitudinal analyses of ctDNA were more predictive of overall survival than standard-of-care radiological response evaluation. ctDNA mutations related to primary or acquired resistance to panitumumab were identified in 42% of patients. Conclusions: Accurate calling of ctDNA mutations for treatment response monitoring is feasible in a tumor tissue–independent manner by combined cfDNA and patient-matched WBC genomic DNA analysis. This tissue biopsy-independent approach simplifies sample logistics and facilitates the application of liquid biopsy ctDNA testing for evaluation of emerging therapy resistance, opening new avenues for early adaptation of treatment regimens.
Diagnostic delays in patients with brain cancer are common and can impact patient outcome. Development of a blood-based assay for detection of brain cancers could accelerate brain cancer diagnosis. In this study, we analyzed genome-wide cell-free (cfDNA) fragmentomes, including fragmentation profiles and repeat landscapes, from the plasma of individuals with (n = 148) or without (n = 357) brain cancer. Machine learning analyses of cfDNA fragmentome features detected brain cancer across all-grade gliomas (AUC = 0.90; 95% confidence interval, 0.87–0.93), and these results were validated in an independent prospectively collected cohort. cfDNA fragmentome changes in patients with gliomas represented a combination of fragmentation profiles from glioma cells and altered white blood cell populations in the circulation. These analyses reveal the properties of cfDNA in patients with brain cancer and open new avenues for noninvasive detection of these individuals. Significance: Brain cancer is one of the deadliest and most challenging cancers to detect with liquid biopsy approaches in blood, hampering efforts for earlier noninvasive diagnosis. We have developed a machine learning genome-wide cfDNA fragmentation method that provides a sensitive and accessible approach for brain cancer detection.
14 March 2024 in International Journal of Radiation Oncology, Biology, Physics
Schematic overview of the study. A, Schematic overview of the study design, including cohort selection and experimental and statistical approaches. TE, transposable element, SINE, short interspersed nuclear elements, LINE, long interspersed nuclear elements, PNS, peripheral nervous system. B, Schematic overview of the systemic and local pathophysiologic alterations in HGGs relevant to cfDNA fragmentation and liquid biopsies. HGGs establish a systemic and local immune-suppressive environment that leads to systemic lymphopenia and infiltration of myeloid-derived suppressor cells in the tumor microenvironment. Apoptotic lymphocytes release cfDNA in the circulation, increasing the contribution of lymphocytes to the total pool of cfDNA fragments compared with individuals without cancer. In the local microenvironment, the blood–brain barrier (BBB) is broken down in the tumor, thus allowing nucleosomal DNA from apoptotic tumor cells and other supporting cells to exit into the circulation.
CfDNA fragmentation and mutations in plasma of patients with HGGs. A, The table shows the number and percentage of patients analyzed and detected with the ARTEMIS–DELFI assay, the tumor-guided mutational panel approach, or both. B, Histogram representation of the sensitivity of HGG detection by the mutation panel or the ARTEMIS–DELFI approach. The score threshold corresponding to 90% specificity is applied to determine the samples detected by ARTEMIS–DELFI approach. The analytical specificity of the tumor-informed mutation panel assay is 99.9%. C, Fragment length distribution of tumor-specific mutant fragments vs. fragments with no mutations, germline mutations or known clonal hematopoiesis of indeterminate potential (CHIP) mutations. Tumor-specific mutations are residing in shorter fragments than wild-type (WT) or nontumor mutant fragments (median length of 146 bp vs. 167 bp, Wilcoxon P < 0.0001).